InvestSMART

Raptor Metals Ltd (ASX: RAP) - Announcements

- Current share price for RAP : $0.028

ASX company news and announcements for Raptor Metals Ltd (RAP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Raptor Metals Ltd (RAP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Raptor Metals Ltd (RAP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Raptor Metals Ltd (RAP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$11 ResApp announces positive results of COVID-19 screening test 22 Mar 2022 9:39AM $0.062 $0.028 fallen by 54.84%
$11 Suspension from Official Quotation 21 Mar 2022 11:43AM $0.062 $0.028 fallen by 54.84%
$11 Trading Halt 17 Mar 2022 9:54AM $0.062 $0.028 fallen by 54.84%
$11 Half Yearly Report and Accounts 25 Feb 2022 9:37AM $0.066 $0.028 fallen by 57.58%
$11 Health Teams to launch ResAppDx on aged care platform 14 Feb 2022 9:43AM $0.070 $0.028 fallen by 60%
$11 Cough analysis patent granted in China 1 Feb 2022 9:30AM $0.075 $0.028 fallen by 62.67%
$11 Quarterly Activities Report and Appendix 4C 28 Jan 2022 9:48AM $0.051 $0.028 fallen by 45.10%
$11 Quarterly Results and Investor Conference Call Notification 27 Jan 2022 9:58AM $0.058 $0.028 fallen by 51.72%
$11 Further appointments to COVID-19 Scientific Advisory Board 27 Jan 2022 9:37AM $0.058 $0.028 fallen by 51.72%
$11 ResAppDx goes live with Doctors on Demand in Australia 24 Jan 2022 9:26AM $0.059 $0.028 fallen by 52.54%
$11 LOI signed with Homify to launch ResAppDx in the Philippines 20 Jan 2022 9:53AM $0.060 $0.028 fallen by 53.33%
$11 Publication highlights use of ResAppDx in COVID-19 clinic 17 Jan 2022 9:36AM $0.059 $0.028 fallen by 52.54%
$11 Notification regarding unquoted securities - RAP 13 Jan 2022 5:14PM $0.065 $0.028 fallen by 56.92%
$11 US COVID-19 study completes recruitment 10 Jan 2022 9:33AM $0.062 $0.028 fallen by 54.84%
$11 ResAppDx goes live with Alodokter in Indonesia 7 Jan 2022 9:25AM $0.060 $0.028 fallen by 53.33%
$11 Distribution agreement with Sanrai International 22 Dec 2021 9:32AM $0.060 $0.028 fallen by 53.33%
$11 Change of Registry Address 20 Dec 2021 2:56PM $0.059 $0.028 fallen by 52.54%
$11 ResApp receives $818,826 in R&D tax incentive refund 20 Dec 2021 9:32AM $0.058 $0.028 fallen by 51.72%
$11 ResApp Establishes COVID-19 Scientific Advisory Board 8 Dec 2021 9:31AM $0.057 $0.028 fallen by 50.88%
$11 Results of Annual General Meeting 30 Nov 2021 6:12PM $0.065 $0.028 fallen by 56.92%
$11 Annual General Meeting Presentation 30 Nov 2021 3:52PM $0.063 $0.028 fallen by 55.56%
$11 Letter to Shareholders 30 Nov 2021 9:12AM $0.059 $0.028 fallen by 52.54%
$11 ResApp receives regulatory approvals for cough counter 29 Nov 2021 9:56AM $0.056 $0.028 fallen by 50%
$11 ResApp completes COVID-19 study recruitment in India 23 Nov 2021 9:56AM $0.055 $0.028 fallen by 49.09%
$11 Publication on challenges of diagnosing respiratory disease 19 Nov 2021 9:53AM $0.054 $0.028 fallen by 48.15%

101 - 125 of 568 results

Page 5 of 23

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.